Université de Montréal has identified compounds acting as proto-oncogene tyrosine-protein kinase Src (SRC; SRC1) and/or tyrosine-protein kinase Yes (YES1) inhibitors reported to be useful for the treatment of cancer, fibrosis and liver diseases.
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. has synthesized prodrugs of kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Bakuchiol, a phenolic meroterpenoid from the seeds of Psoralea corylifolia L., has shown promise as an antitumor drug, so researchers at Bengbu Medical University synthesized novel derivatives of bakuchiol bearing modifications on the aromatic ring.
Vaxcellbio Co. Ltd. has signed a research agreement with the Korea Drug Development Fund (KDDF) to pursue the discovery of next-generation targeted anticancer lead compounds based on degradation of the molecular motor protein MYO1D (myosin 1D).
Fibrolamellar carcinoma (FLC) is a rare and lethal cancer accounting for 1% of liver cancers affecting young, otherwise healthy patients. The primary driver of the vast majority of human FLCs is a fusion between the heat shock protein 40 (DNAJB1) and the catalytic subunit α of protein kinase A (PRKACA).
Peptidream Inc. has submitted IND applications to the FDA to initiate phase I studies of [225Ac]PD-32766, as a potential radiotherapeutic, and [64Cu]PD-32766, as the radiodiagnostic pair, for patients with clear cell renal cell carcinoma (ccRCC).
Researchers from Johns Hopkins University, National Institutes of Health and University of Iowa have synthesized superstolide derivatives reported to be useful for the treatment of cancer and viral infections.
Triple-negative breast cancer, which accounts for 15-20% of all cases of breast cancer, is particularly difficult to treat. It is driven in part by epidermal growth factor receptor (EGFR), yet EGFR inhibitors that are effective against other cancers somehow fail to be effective against triple-negative breast cancer.
Researchers from Eilean Therapeutics LLC and collaborators presented the discovery and characterization of a new, selective CDK2 inhibitor showing potent in vitro and in vivo activity at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
RSS
